interactions:
- request:
    body: ''
    headers:
      accept:
      - '*/*'
      accept-encoding:
      - gzip, deflate
      connection:
      - keep-alive
      host:
      - api.crossref.org
      user-agent:
      - python-httpx/0.27.2 habanero/2.3.0
      x-user-agent:
      - python-httpx/0.27.2 habanero/2.3.0
    method: GET
    uri: https://api.crossref.org/works?sample=2
  response:
    content: '{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":2,"items":[{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:28Z","timestamp":1740107428837,"version":"3.37.3"},"reference-count":19,"publisher":"Springer
      Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer
      Chemother Pharmacol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00280-016-3089-4","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:33:07Z","timestamp":1466641987000},"page":"361-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["TACTIC:
      a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin,
      and gemcitabine in biliary tract cancer"],"prefix":"10.1007","volume":"78","author":[{"name":"behalf
      of the the Australasian Gastro-Intestinal Trials Group","sequence":"first","affiliation":[]},{"given":"D.","family":"Ferraro","sequence":"first","affiliation":[]},{"given":"D.","family":"Goldstein","sequence":"additional","affiliation":[]},{"given":"R.
      L.","family":"O\u2019Connell","sequence":"additional","affiliation":[]},{"given":"J.
      R.","family":"Zalcberg","sequence":"additional","affiliation":[]},{"given":"K.
      M.","family":"Sjoquist","sequence":"additional","affiliation":[]},{"given":"N.
      C.","family":"Tebbutt","sequence":"additional","affiliation":[]},{"given":"P.","family":"Grimison","sequence":"additional","affiliation":[]},{"given":"S.","family":"McLachlan","sequence":"additional","affiliation":[]},{"given":"L.
      L.","family":"Lipton","sequence":"additional","affiliation":[]},{"given":"P.","family":"Vasey","sequence":"additional","affiliation":[]},{"given":"V.
      J.","family":"Gebski","sequence":"additional","affiliation":[]},{"given":"C.","family":"Aiken","sequence":"additional","affiliation":[]},{"given":"M.","family":"Cronk","sequence":"additional","affiliation":[]},{"given":"S.","family":"Ng","sequence":"additional","affiliation":[]},{"given":"C.
      S.","family":"Karapetis","sequence":"additional","affiliation":[]},{"given":"J.","family":"Shannon","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"issue":"3","key":"3089_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/(sici)1096-9098(199703)64:3<242::aid-jso12>3.0.co;2-6","volume":"64","author":"TP
      Wade","year":"1997","unstructured":"Wade TP, Prasad CN, Virgo KS, Johnson FE
      (1997) Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals:
      1987\u20131991. J Surg Oncol 64(3):242\u2013245. doi: 10.1002\/(sici)1096-9098(199703)64:3<242:aid-jso12>3.0.co;2-6","journal-title":"J
      Surg Oncol"},{"issue":"15","key":"3089_CR2","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.ejca.2015.07.034","volume":"51","author":"C
      Lepage","year":"2015","unstructured":"Lepage C, Capocaccia R, Hackl M, Lemmens
      V, Molina E, Pierannunzio D, Sant M, Trama A, Faivre J (2015) Survival in patients
      with primary liver cancer, gallbladder and extrahepatic biliary tract cancer
      and pancreatic cancer in Europe 1999\u20132007: results of EUROCARE-5. Eur J
      Cancer 51(15):2169\u20132178. doi: 10.1016\/j.ejca.2015.07.034","journal-title":"Eur
      J Cancer"},{"issue":"14","key":"3089_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/nejmoa0908721","volume":"362","author":"J
      Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham
      D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton
      M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary
      tract cancer. N Engl J Med 362(14):1273\u20131281. doi: 10.1056\/nejmoa0908721","journal-title":"N
      Engl J Med"},{"issue":"11","key":"3089_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/nejmra0707704","volume":"358","author":"F
      Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G (2008) EGFR
      antagonists in cancer treatment. N Engl J Med 358(11):1160\u20131174. doi: 10.1056\/nejmra0707704","journal-title":"N
      Engl J Med"},{"issue":"12","key":"3089_CR5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/s1470-2045(10)70247-3","volume":"11","author":"B
      Gruenberger","year":"2010","unstructured":"Gruenberger B, Schueller J, Heubrandtner
      U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T
      (2010) Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable
      advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 11(12):1142\u20131148.
      doi: 10.1016\/s1470-2045(10)70247-3","journal-title":"Lancet Oncol"},{"issue":"12","key":"3089_CR6","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","volume":"24","author":"DPS
      Sohal","year":"2013","unstructured":"Sohal DPS, Mykulowycz K, Uehara T, Teitelbaum
      UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O\u2019Dwyer
      PJ, Sepulveda A, Sun W (2013) A phase II trial of gemcitabine, irinotecan and
      panitumumab in advanced cholangiocarcinoma. Ann Oncol 24(12):3061\u20133065.
      doi: 10.1093\/annonc\/mdt416","journal-title":"Ann Oncol"},{"issue":"9","key":"3089_CR7","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mds008","volume":"23","author":"LH
      Jensen","year":"2012","unstructured":"Jensen LH, Lindebjerg J, Ploen J, Hansen
      TF, Jakobsen A (2012) Phase II marker-driven trial of panitumumab and chemotherapy
      in KRAS wild-type biliary tract cancer. Ann Oncol 23(9):2341\u20132346. doi:
      10.1093\/annonc\/mds008","journal-title":"Ann Oncol"},{"issue":"2","key":"3089_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s1470-2045(11)70301-1","volume":"13","author":"J
      Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, Kim JS, Choi HJ,
      Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO,
      Park YS, Kang WK, Lim HY (2012) Gemcitabine and oxaliplatin with or without
      erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised,
      phase 3 study. Lancet Oncol 13(2):181\u2013188. doi: 10.1016\/s1470-2045(11)70301-1","journal-title":"Lancet
      Oncol"},{"issue":"3","key":"3089_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00280-010-1351-8","volume":"67","author":"D
      Goldstein","year":"2010","unstructured":"Goldstein D, Gainford MC, Brown C,
      Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski
      V, Miller D, Shannon J (2010) Fixed-dose-rate gemcitabine combined with cisplatin
      in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol
      67(3):519\u2013525. doi: 10.1007\/s00280-010-1351-8","journal-title":"Cancer
      Chemother Pharmacol"},{"issue":"2","key":"3089_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s10620-007-9885-2","volume":"53","author":"JA
      Meyerhardt","year":"2007","unstructured":"Meyerhardt JA, Zhu AX, Stuart K, Ryan
      DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS (2007)
      Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary
      and gallbladder cancer. Dig Dis Sci 53(2):564\u2013570. doi: 10.1007\/s10620-007-9885-2","journal-title":"Dig
      Dis Sci"},{"issue":"1","key":"3089_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R
      Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs
      for phase II clinical trials. Control Clin Trials 10(1):1\u201310. doi: 10.1016\/0197-2456(89)90015-9","journal-title":"Control
      Clin Trials"},{"key":"3089_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/9781118032619","volume-title":"Analysis
      of health surveys","author":"EL Korn","year":"1999","unstructured":"Korn EL,
      Graubard BI (1999) Analysis of health surveys. Wiley, Blackwell, New York. doi:
      10.1002\/9781118032619"},{"issue":"4","key":"3089_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M
      Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on
      quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346.
      doi: 10.1016\/0197-2456(96)00075-x","journal-title":"Control Clin Trials"},{"issue":"9314","key":"3089_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/s0140-6736(02)08272-7","volume":"359","author":"TG
      Clark","year":"2002","unstructured":"Clark TG, Altman DG, Stavola BLD (2002)
      Quantification of the completeness of follow-up. Lancet 359(9314):1309\u20131310.
      doi: 10.1016\/s0140-6736(02)08272-7","journal-title":"Lancet"},{"issue":"8","key":"3089_CR15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/s1470-2045(14)70212-8","volume":"15","author":"D
      Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach
      T, de la Fouchardi\u00e8re C, Boucher E, Fartoux L, Faivre S, Blanc J-F, Viret
      F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, Andr\u00e9
      T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon J-P, Wendum D, Rosmorduc
      O, Greten TF (2014) Gemcitabine and oxaliplatin with or without cetuximab in
      advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative
      phase 2 trial. Lancet Oncol 15(8):819\u2013828. doi: 10.1016\/s1470-2045(14)70212-8","journal-title":"Lancet
      Oncol"},{"issue":"8","key":"3089_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/s1470-2045(14)70238-4","volume":"15","author":"JW
      Valle","year":"2014","unstructured":"Valle JW (2014) BINGO: targeted therapy
      for advanced biliary-tract cancer. Lancet Oncol 15(8):778\u2013780. doi: 10.1016\/s1470-2045(14)70238-4","journal-title":"Lancet
      Oncol"},{"issue":"5","key":"3089_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/annonc\/mdv035","volume":"26","author":"JS
      Chen","year":"2015","unstructured":"Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou
      HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau
      KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT, Taiwan Cooperative
      Oncology G, Shen WC, Hsu HC, Hsu CH, Shen YC, Wang TE, Li CP, Chen MH, Kao WY,
      Chang PY, Wu CC, Teng CL, Lu CH, Lin SJ, Wang BW, Chen YY, Chin YH, Chung TR,
      Yu WL, Lee MH, Lin LF, Lin PC, Wu YL, Wang HL, Lu LJ, Chen SY, Wu CC, Wei TC
      (2015) A KRAS mutation status-stratified randomized phase II trial of gemcitabine
      and oxaliplatin alone or in combination with cetuximab in advanced biliary tract
      cancer. Ann Oncol 26(5):943\u2013949. doi: 10.1093\/annonc\/mdv035","journal-title":"Ann
      Oncol"},{"issue":"1","key":"3089_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ
      Sorich","year":"2014","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse
      G, McKinnon RA, Karapetis CS (2014) Extended RAS mutations and anti-EGFR monoclonal
      antibody survival benefit in metastatic colorectal cancer: a meta-analysis of
      randomized, controlled trials. Ann Oncol 26(1):13\u201321. doi: 10.1093\/annonc\/mdu378","journal-title":"Ann
      Oncol"},{"issue":"8","key":"3089_CR19","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ijc.28153","volume":"133","author":"Z-Y
      Yang","year":"2013","unstructured":"Yang Z-Y, Wu X-Y, Huang Y-F, Di M-Y, Zheng
      D-Y, Chen J-Z, Ding H, Mao C, Tang J-L (2013) Promising biomarkers for predicting
      the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated
      with anti-epidermal growth factor receptor monoclonal antibodies: a systematic
      review with meta-analysis. Int J Cancer 133(8):1914\u20131925. doi: 10.1002\/ijc.28153","journal-title":"Int
      J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3089-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3089-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3089-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T04:28:56Z","timestamp":1469680136000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3089-4"}},"issued":{"date-parts":[[2016,6,22]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3089-4","ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"published":{"date-parts":[[2016,6,22]]}},{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T01:41:32Z","timestamp":1648690892035},"reference-count":0,"publisher":"American
      Library Association","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Choice
      Reviews Online"],"published-print":{"date-parts":[[1992,5,1]]},"DOI":"10.5860\/choice.29-5410","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T00:56:18Z","timestamp":1358988978000},"page":"29-5410-29-5410","source":"Crossref","is-referenced-by-count":0,"title":["Porn:
      myths for the twentieth century"],"prefix":"10.5860","volume":"29","member":"3932","container-title":["Choice
      Reviews Online"],"language":"en","deposited":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T16:37:32Z","timestamp":1470933452000},"score":0.0,"resource":{"primary":{"URL":"http:\/\/choicereviews.org\/review\/10.5860\/CHOICE.29-5410"}},"issued":{"date-parts":[[1992,5,1]]},"references-count":0,"journal-issue":{"issue":"09","published-print":{"date-parts":[[1992,5,1]]}},"URL":"https:\/\/doi.org\/10.5860\/choice.29-5410","ISSN":["0009-4978","1523-8253"],"issn-type":[{"value":"0009-4978","type":"print"},{"value":"1523-8253","type":"electronic"}],"published":{"date-parts":[[1992,5,1]]}}],"items-per-page":20,"query":{"start-index":0,"search-terms":null}}}'
    headers:
      Connection:
      - keep-alive
      Content-Length:
      - '5033'
      Content-Type:
      - application/json
      Date:
      - Sat, 12 Jul 2025 04:28:55 GMT
      access-control-allow-headers:
      - X-Requested-With, Accept, Accept-Encoding, Accept-Charset, Accept-Language,
        Accept-Ranges, Cache-Control
      access-control-allow-origin:
      - '*'
      access-control-expose-headers:
      - Link
      content-encoding:
      - gzip
      permissions-policy:
      - interest-cohort=()
      server:
      - Jetty(9.4.40.v20210413)
      vary:
      - Accept-Encoding
      x-api-pool:
      - public
      x-ratelimit-interval:
      - 1s
      x-ratelimit-limit:
      - '50'
    http_version: HTTP/1.1
    status_code: 200
version: 1
